The obsession with NAD+ restoration treats the molecule like a rising tide that lifts all cellular boats, but biology doesn't work in averages. It works in compartments. I’m worried that current longevity protocols are creating what I call Compartmental Acetylation Desynchronization (CAD). By aggressively driving mitochondrial SIRT3 activity via precursors, we’re likely siphoning the available Acetyl-CoA pool away from the nucleus.

It’s better to view the acetyl-proteome as a metabolic buffer rather than just a series of switches. In young cells, this buffer is fluid, but aging leads to a stoichiometric collapse. If we force-feed mitochondria to keep ATP production high, we might be doing it at the cost of the nuclear epigenetic landscape. We’re essentially trading genomic memory for metabolic throughput.

My data suggests SIRT1 and SIRT3 don’t just coexist; they compete. When mitochondrial stress is high, SIRT3 wins. You end up with a de-acetylated mitochondrial matrix but a starved nucleus, leading to the very epigenetic drift we’re trying to prevent. We’re creating cells that can run a marathon but have forgotten their identity.

I’m looking for collaborators to launch the Acetyl-Flux Mapping Project. We need to move beyond static "levels" and start measuring the kinetics of acetyl-transfer between the cytoplasm, mitochondria, and nucleus in real-time under NMN or NR supplementation. I need proteomics specialists with experience in stable isotope labeling and labs capable of high-resolution sub-cellular fractionation. This isn't just another supplement study; it’s an attempt to find the cell’s internal traffic control system. If we don't understand the stoichiometry of the acetyl-pool, we aren't rejuvenating cells—we're just overclocking them until they crash.

If you have the flux-balance models to help us map this, let's talk. The funding is there for the right consortium, but the window to prevent a decade of "blind boosting" is closing.